This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.
Histologically documented advanced or metastatic solid tumor with KRAS G12D mutation
Agreement to adhere to the contraception requirements described in the protocol for participants of childbearing potential and participants who produce sperm
Malabsorption or other condition that would interfere with enteral absorption
Active brain metastases
Clinically significant cardiovascular dysfunction or liver disease